By analyzing pairs of primary and metastatic tumors we identified two novel genes linked to adverse clinical course: KMT2C and EPHA7. The TCGA data suggest that patients with alterations in those genes in the primary tumor have a high risk of death, in particular early during the adjuvant hormonal treatment. Here, KMT2C is linked to metastatic neoplasm.